Philadelphia, PENNSYLVANIA1 Active Studies

Parkinsons Disease Clinical Trials in Philadelphia, PENNSYLVANIA

Find 1 actively recruiting parkinsons disease clinical trials in Philadelphia, PENNSYLVANIA. Connect with local research sites and explore new treatment options.

1
Active Trials
1
Sponsors
20
Enrolling

Recruiting Parkinsons Disease Studies in Philadelphia

About Parkinsons Disease Clinical Trials in Philadelphia

Parkinson's disease is a progressive nervous system disorder that affects movement, causing tremors, stiffness, and difficulty with balance. It results from the loss of dopamine-producing neurons in the brain. Treatment includes medications, deep brain stimulation, and emerging therapies targeting disease modification.

There are currently 1 parkinsons disease clinical trials recruiting participants in Philadelphia, PENNSYLVANIA. These studies are seeking a combined 20 participants. Research is being sponsored by Prevail Therapeutics. Clinical trial participation is free and participants receive study-related medical care at no cost.

Parkinsons Disease Clinical Trials in Philadelphia — FAQ

Are there parkinsons disease clinical trials in Philadelphia?

Yes, there are 1 parkinsons disease clinical trials currently recruiting in Philadelphia, PENNSYLVANIA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Philadelphia?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Philadelphia research site will contact you about next steps.

Are clinical trials in Philadelphia free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Philadelphia studies also compensate for your time and travel.

What parkinsons disease treatments are being tested?

The 1 active trials in Philadelphia are testing new therapies including novel drugs, biologics, and treatment approaches for parkinsons disease.

Data updated March 2, 2026 from ClinicalTrials.gov